Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.
Non-Small Cell Lung Cancer (NSCLC)
DRUG: ABT-869 .25 mg/kg|DRUG: ABT-869 0.10 mg/kg
Progression Free Rate (PFR), Week 16
Objective Response Rate, Week 16
The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.